Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perspective
  • Published:

First, a seat; then, an upgrade

Journal of Human Hypertension volume 38, pages 620–623 (2024)Cite this article

Subjects

Abstract

The Sir Stanley Peart Essay Competition is an annual event run by the British and Irish Hypertension Society to encourage Early Career Researchers to continue the ethos of Sir Stanley Peart. Sir Stanley Peart was a clinician and clinical researcher who made a major contribution to our understanding of blood pressure regulation. He was the first to demonstrate the release of noradrenaline in response to sympathetic nerve stimulation. He was also the first to purify, and determine the structure of, angiotensin and he later isolated the enzyme, renin, and carried out many important investigations of the factors controlling its release in the body. This year, the essay topic was “Do we need new classes of antihypertensive drugs?”. In his prize-winning essay, "First, a seat; then, an upgrade", Dr Sathyanarayanan argues that we do not need new classes of antihypertensive drugs, instead we should focus our attention on addressing the factors that lead to high blood pressure in the first place and use our existing drug classes more effectively.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Delveinsight. Treatment-Resistant Hypertension - Market Insight, Epidemiology And Market Forecast - 2032. 2022. https://www.delveinsight.com/report-store/treatment-resistant-hypertension-market.

  2. Ojha U, Ruddaraju S, Sabapathy N, Ravindran V, Worapongsatitaya P, Haq J, et al. Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension. Am J Cardiovasc Drugs. 2022;22:271–85.

    Article  PubMed  Google Scholar 

  3. Singh NK, Goyal RK. New Classes of Antihypertensive Drugs: Therapeutic Potentials. Clin Exp Hypertens. 1999;21:137–43.

    Article  CAS  PubMed  Google Scholar 

  4. Chen V, Ning H, Allen N, Kershaw K, Khan S, Lloyd-Jones DM, et al. Lifetime Risks for Hypertension by Contemporary Guidelines in African American and White Men and Women. JAMA Cardiol. 2019;4:455.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957–80.

    Article  Google Scholar 

  6. Gurven M, Blackwell AD, Rodríguez DE, Stieglitz J, Kaplan H. Does Blood Pressure Inevitably Rise With Age? Hypertension. 2012;60:25–33.

    Article  CAS  PubMed  Google Scholar 

  7. Angeli F, Reboldi G, Verdecchia P. Modernization and hypertension: is the link changing? Hypertens Res. 2013;36:676–8.

    Article  PubMed  Google Scholar 

  8. Angeli F, Reboldi G, Verdecchia P. “From Apennines to Andes:” Does Body Mass Index Affect the Relationship Between Age and Blood Pressure? Hypertension. 2012;60:6–7.

    Article  CAS  PubMed  Google Scholar 

  9. Guerrero-García C, Rubio-Guerra F. Combination therapy in the treatment of hypertension. Drugs Context. 2018;7:1–9.

    Article  Google Scholar 

  10. Yamout H, Bakris G. Initial Combination Therapies. In: Bakris G, Sorrentino M, Laffin L, editors. Hypertension: A Companion to Braunwald’s Heart Disease, 4th ed. Philadelphia, USA: Elsevier; 2024. p. 304–9.

  11. Rouette J, McDonald EG, Schuster T, Brophy JM, Azoulay L. Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study. BMJ Open. 2022;12:e057510.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Chilton RJ, Silva-Cardoso J. Mineralocorticoid receptor antagonists in cardiovascular translational biology. Cardiovasc Endocrinol Metab. 2023;12:e0289.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Heran BS, Galm BP, Wright JM. Blood pressure lowering efficacy of alpha blockers for primary hypertension. Cochrane Database Syst Rev. 2012;15:CD004643.

  14. McComb MN, Chao JY, Ng TMH. Direct Vasodilators and Sympatholytic Agents. J Cardiovasc Pharm Ther. 2016;21:3–19.

    Article  CAS  Google Scholar 

  15. Bousquet P, Hudson A, García-Sevilla JA, Li JX. Imidazoline Receptor System: The Past, the Present, and the Future. Pharm Rev. 2020;72:50–79.

    Article  CAS  PubMed  Google Scholar 

  16. Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension 2019;73:424–31.

    Article  CAS  PubMed  Google Scholar 

  17. Yoon M, You SC, Oh J, Lee CJ, Lee SH, Kang SM, et al. Prevalence and prognosis of refractory hypertension diagnosed using ambulatory blood pressure measurements. Hypertens Res. 2022;45:1353–62.

    Article  CAS  PubMed  Google Scholar 

  18. Burnier M, Egan BM. Adherence in Hypertension. Circ Res. 2019;124:1124–40.

    Article  CAS  PubMed  Google Scholar 

  19. Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of Resistant and Refractory Hypertension. Circ Res. 2019;124:1061–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Leggio M, Lombardi M, Caldarone E, Severi P, D’Emidio S, Armeni M, et al. The relationship between obesity and hypertension: an updated comprehensive overview on vicious twins. Hypertens Res. 2017;40:947–63.

    Article  PubMed  Google Scholar 

  21. Kannel WB, Brand N, Skinner JJ, Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension. The Framingham study. Ann Intern Med. 1967;67:48–59.

    Article  CAS  PubMed  Google Scholar 

  22. Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331:38–48.

    Article  CAS  PubMed  Google Scholar 

  24. Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes. 2024 https://doi.org/10.1038/s41366-024-01473-y.

  25. Harris E. Tirzepatide Lowered Blood Pressure in People With Obesity. JAMA. 2024;331:821.

    PubMed  Google Scholar 

  26. Kennedy C, Hayes P, Salama S, Hennessy M, Fogacci F. The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis. J Clin Med. 2023;12:772.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, et al. Effect of Salt Substitution on Cardiovascular Events and Death. N Engl J Med. 2021;385:1067–77.

    Article  CAS  PubMed  Google Scholar 

  28. Yin X, Rodgers A, Perkovic A, Huang L, Li KC, Yu J, et al. Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis. Heart. 2022;108:1608–15.

    Article  CAS  PubMed  Google Scholar 

  29. Xu X, Zeng L, Jha V, Cobb LK, Shibuya K, Appel LJ, et al. Potassium-Enriched Salt Substitutes: A Review of Recommendations in Clinical Management Guidelines. Hypertension. 2024;81:400–14.

    Article  CAS  PubMed  Google Scholar 

  30. Partearroyo T, Samaniego-Vaesken ML, Ruiz E, Aranceta-Bartrina J, Gil Á, González-Gross M, et al. Sodium Intake from Foods Exceeds Recommended Limits in the Spanish Population: The ANIBES Study. Nutrients. 2019;11:2451.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kissock KR, Garrett GS, Mkambula P, Bullen JD, Trieu K, Fisher LJ, et al. Switching the World’s Salt Supply-Learning from Iodization to Achieve Potassium Enrichment. Adv Nutr. 2024;15:100148.

    Article  CAS  PubMed  Google Scholar 

  32. Vartiainen E. The North Karelia Project: Cardiovascular disease prevention in Finland. Glob Cardiol Sci Pr. 2018;2018:13.

    Google Scholar 

  33. Lee EW, Kim HS, Yoo BN, Lee EJ, Park JH. Effect of a Primary Care-Based Chronic Disease Management Program for Hypertension Patients in South Korea. Iran J Public Health. 2022;51:624–33.

    PubMed  PubMed Central  Google Scholar 

  34. World Bank and WHO: Half the world lacks access to essential health services, 100 million still pushed into extreme poverty because of health expenses. 2017. https://www.who.int/news/item/13-12-2017-world-bank-and-who-half-the-world-lacks-access-to-essential-health-services-100-million-still-pushed-into-extreme-poverty-because-of-health-expenses.

  35. The World Bank. Poverty. 2024. https://www.worldbank.org/en/topic/poverty/overview.

  36. Langlois EV, McKenzie A, Schneider H, Mecaskey JW. Measures to strengthen primary health-care systems in low- and middle-income countries. Bull World Health Organ. 2020;98:781–91.

    Article  PubMed  PubMed Central  Google Scholar 

  37. The World Factbook. Country Comparisons Infant mortality rate. 2024. https://www.cia.gov/the-world-factbook/field/infant-mortality-rate/country-comparison/.

  38. Lubega J, Kimutai RL, Chintagumpala MM. Global health disparities in childhood cancers. Curr Opin Pediatr. 2021;33:33–9.

    Article  PubMed  Google Scholar 

  39. Schutte AE, Srinivasapura Venkateshmurthy N, Mohan S, Prabhakaran D. Hypertension in Low- and Middle-Income Countries. Circ Res. 2021;128:808–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Desai M, Stockbridge N, Temple R. Blood pressure as an example of a biomarker that functions as a surrogate. AAPS J. 2006;8:E146–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Chen Y, Lei L, Wang JG. Methods of Blood Pressure Assessment Used in Milestone Hypertension Trials. Pulse. 2018;6:112–23.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Zhou B, Bentham J, Di Cesare M, Bixby H, Danaei G, Hajifathalian K, et al. Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants. Int J Epidemiol. 2018;47:872–883i.

    Article  Google Scholar 

  43. Kwak SG, Kim JH. Central limit theorem: the cornerstone of modern statistics. Korean J Anesthesiol. 2017;70:144.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Pater C. The Blood Pressure “Uncertainty Range” - a pragmatic approach to overcome current diagnostic uncertainties (II). Curr Control Trials Cardiovasc Med. 2005;6:5.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Bo Y, Kwok KO, Chung VCH, Yu CP, Tsoi KKF, Wong SYS, et al. Short-term reproducibility of ambulatory blood pressure measurements: a systematic review and meta-analysis of 35 observational studies. J Hypertens. 2020;38:2095–109.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Varghese JS, Venkateshmurthy NS, Sudharsanan N, Jeemon P, Patel SA, Thirumurthy H, et al. Hypertension Diagnosis, Treatment, and Control in India. JAMA Netw Open. 2023;6:e2339098.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Dhillon J, Jacobs AG, Ortiz S, Diaz Rios LK. A Systematic Review of Literature on the Representation of Racial and Ethnic Minority Groups in Clinical Nutrition Interventions. Adv Nutr. 2022;13:1505–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Singh RB, Nabavizadeh F, Fedacko J, Pella D, Vanova N, Jakabcin P, et al. Dietary Approaches to Stop Hypertension via Indo-Mediterranean Foods, May Be Superior to DASH Diet Intervention. Nutrients. 2022;15:46.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Jeong SY, Wee CC, Kovell LC, Plante TB, Miller ER, Appel LJ, et al. Effects of Diet on 10-Year Atherosclerotic Cardiovascular Disease Risk (from the DASH Trial). Am J Cardiol. 2023;187:10–7.

    Article  PubMed  Google Scholar 

  50. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A Clinical Trial of the Effects of Dietary Patterns on Blood Pressure. N Engl J Med. 1997;336:1117–24.

    Article  CAS  PubMed  Google Scholar 

  51. Chibuzo INC, Takure AO, Shittu OB, Okeke LI. Cosmetic Appeal, HRQoL, and Effectiveness of Simple and Pseudotesticular Techniques of Orchidectomy in Prostate Cancer. Prostate Cancer. 2021;2021:1–12.

    Article  Google Scholar 

  52. Paula AAP, de Piccelli HRS, Pinto NP, Teles AG, Franqueiro AG, Maltez ARL, et al. Economical impact of orchiectomy for advanced prostate cancer. Int Braz J Urol. 2003;29:127–32.

    Article  PubMed  Google Scholar 

  53. Weiner AB, Cohen JE, DeLancey JO, Schaeffer EM, Auffenberg GB. Surgical versus Medical Castration for Metastatic Prostate Cancer: Use and Overall Survival in a National Cohort. J Urol. 2020;203:933–9.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Trussell J, Lalla AM, Doan QV, Reyes E, Pinto L, Gricar J. Cost effectiveness of contraceptives in the United States. Contraception 2009;79:5–14.

    Article  PubMed  Google Scholar 

  55. Faria R, Bojke L, Epstein D, Corbacho B, Sculpher M. Cost-effectiveness of laparoscopic fundoplication versus continued medical management for the treatment of gastro-oesophageal reflux disease based on long-term follow-up of the REFLUX trial. Br J Surg. 2013;100:1205–13.

    Article  CAS  PubMed  Google Scholar 

  56. Kitschen A, Aleknonytė‐Resch M, Sakalytė G, Diederich F. Cost‐effectiveness of surgical treatment compared to medical treatment in patients with drug‐refractory epilepsy: A systematic review. Eur J Neurol. 2023;30:749–61.

    Article  PubMed  Google Scholar 

  57. Haridoss M, Kumar S, Natarajan M, Sasidharan A, Rajsekar K, Oswal NK, et al. Cost-effectiveness of cholecystectomy compared to conservative management in people presenting with uncomplicated symptomatic gallstones or cholecystitis in India. Expert Rev Pharmacoecon Outcomes Res. 2023;23:215–24.

    Article  PubMed  Google Scholar 

  58. Kerwat D, Zargaran A, Bharamgoudar R, Arif N, Bello G, Sharma B, et al. Early laparoscopic cholecystectomy is more cost-effective than delayed laparoscopic cholecystectomy in the treatment of acute cholecystitis. Clinico Econ Outcomes Res. 2018;10:119–25.

    Article  Google Scholar 

  59. Jami O, Tijani Y, Et-tahir A. Device-Based Therapy for Resistant Hypertension: An Up‐to‐Date Review. High Blood Pressure Cardiovasc Prevent. 2022 ;29:537–46.

    Article  CAS  Google Scholar 

  60. Grimes CE, Henry JA, Maraka J, Mkandawire NC, Cotton M. Cost‐effectiveness of Surgery in Low‐ and Middle‐income Countries: A Systematic Review. World J Surg. 2014;38:252–63.

    Article  PubMed  Google Scholar 

  61. Jumbam DT, Reddy CL, Roa L, Meara JG. How much does it cost to scale up surgical systems in low-income and middle-income countries? BMJ Glob Health. 2019;4:e001779.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Vaidya A, Hundemer GL, Nanba K, Parksook WW, Brown JM. Primary Aldosteronism: State-of-the-Art Review. Am J Hypertens. 2022;35:967–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The Unrecognized Prevalence of Primary Aldosteronism. Ann Intern Med. 2020;173:10–20.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Ruhle BC, White MG, Alsafran S, Kaplan EL, Angelos P, Grogan RH. Keeping primary aldosteronism in mind: Deficiencies in screening at-risk hypertensives. Surgery. 2019;165:221–7.

    Article  PubMed  Google Scholar 

  65. Powlson AS, Gurnell M, Brown MJ. Nuclear imaging in the diagnosis of primary aldosteronism. Curr Opin Endocrinol Diab Obes. 2015;22:150–6.

    Article  CAS  Google Scholar 

  66. Wu X, Senanayake R, Goodchild E, Bashari WA, Salsbury J, Cabrera CP, et al. [11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial. Nat Med. 2023;29:190–202.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Funder JW. Primary aldosteronism as a public health issue. Lancet Diab Endocrinol. 2016;4:972–3.

    Article  Google Scholar 

  68. Funder JW. Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control. 2013;6:129–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. World Health Organization. Hypertension. 2023. https://www.who.int/news-room/fact-sheets/detail/hypertension.

  70. Wachtel H, Fraker DL. Therapeutic Outcomes with Surgical and Medical Management of Primary Aldosteronism. Curr Cardiol Rep. 2021;23:89.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:1889–916.

    Article  CAS  PubMed  Google Scholar 

  72. NICE guideline [NG136]. Hypertension in adults: diagnosis and management. 2023. https://www.nice.org.uk/guidance/ng136.

  73. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334–57.

    Article  CAS  PubMed  Google Scholar 

  74. Morimoto R, Ono Y, Tezuka Y, Kudo M, Yamamoto S, Arai T, et al. Rapid Screening of Primary Aldosteronism by a Novel Chemiluminescent Immunoassay. Hypertension. 2017;70:334–41.

    Article  CAS  PubMed  Google Scholar 

  75. Brown MJ. Rapid Diagnosis of Primary Aldosteronism. Hypertension. 2017;70:247–9.

    Article  CAS  PubMed  Google Scholar 

  76. Kontis V, Cobb LK, Mathers CD, Frieden TR, Ezzati M, Danaei G. Three Public Health Interventions Could Save 94 Million Lives in 25 Years. Circulation. 2019;140:715–25.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

I would like to thank the Stanley Peart Essay Judges for their expert review of this manuscript: Professor Peter Sever, Professor Ian Wilkinson, Professor Philip Chowienczyk, and Dr Sarah Partridge.

Author information

Authors and Affiliations

  1. Nottingham University Hospitals, Derby Rd, Lenton, Nottingham, NG7 2UH, UK

    Abilash Sathyanarayanan

Authors
  1. Abilash Sathyanarayanan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AS wrote the manuscript.

Corresponding author

Correspondence to Abilash Sathyanarayanan.

Ethics declarations

Competing interests

Professor Phil Chowienczyk has an interest in Centron Diagnostics, a company that has produced technology for blood pressure measurement. Professor Ian B Wilkinson has received research grants from AstraZeneca, GSK and scientific advisory board consultation fees for Viatris, Astra Zeneca and Roche. Dr Abilash Sathyanarayanan, Dr Sarah Partridge and Professor Peter Sever have no competing interests to declare for this manuscript.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sathyanarayanan, A. First, a seat; then, an upgrade. J Hum Hypertens 38, 620–623 (2024). https://doi.org/10.1038/s41371-024-00933-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41371-024-00933-2

Search

Advanced search

Quick links